Antithrombin III Deficiency
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
GrifolsNEW YORK, NY
2 programsAntithrombin IIIPHASE_21 trial
Plasma-derived AT-III concentratePHASE_2_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
OctapharmaAtenativ
GrifolsPlasma-derived AT-III concentrate
GrifolsAntithrombin III
Clinical Trials (3)
Total enrollment: 82 patients across 3 trials
Atenativ Effect on Uterine Blood Flow and Preeclampsia
Start: Jan 2016Est. completion: May 20170
Phase 4Withdrawn
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
Start: Jan 2006Est. completion: Mar 202930 patients
Phase 2/3Active Not Recruiting
Antithrombin III in Infectious Disease Caused by COVID-19
Start: Jul 2021Est. completion: Mar 202252 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.